MedImmune Ventures, Inc. is a wholly owned venture capital subsidiary of MedImmune, Inc. It was created in 2002 to leverage the company’s expertise in discovering, developing and commercializing biotechnology products, as well as its financial resources, to transform new ideas in biotechnology into successful products and companies.
MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies focused on discovering and developing human therapeutics. MedImmune Ventures primarily seeks to invest in areas of strategic interest to MedImmune, including infectious diseases, cancer and inflammatory diseases.
The assessment of new investment opportunities is conducted by a team of experts at MedImmune, led by Ed Mathers, MedImmune’s executive vice president of corporate development and venture; Franklin Top, senior vice president, MedImmune Ventures; and Joseph Amprey, principal, MedImmune Ventures. The MedImmune Ventures investment committee leverages the expertise of the company’s research and development, clinical, sales and marketing, intellectual property, regulatory, corporate development, legal and finance departments.
Seeded with an initial $100 million in 2002 and allocated an additional $100 million in February 2005, MedImmune Ventures invests up to $20 million per company with an average investment of about $7 million. To date, the fund has invested in a number of promising young companies, including: Applied Genetic Technologies Corp.; Critical Therapeutics, Inc.; Elusys Therapeutics, Inc.; Inotek Pharmaceuticals Corp.; Iomai Corp.; Kémia, Inc; Metastatix, Inc.; Micromet AG; Rib-X Pharmaceuticals, Inc.; Sequoia Pharmaceuticals, Inc.; Tercica, Inc.; VaxInnate Corp.; VLST Corporation; and Xencor, Inc.
For more information about Medimmune Ventures, please visit their website.
